maplirpacept + azacitidine + venetoclax

Maplirpacept + azacitidine + venetoclax is an investigational three-drug combination for the treatment of hematological malignancies, particularly acute myeloid leukemia (AML). Maplirpacept (PF-07901801) is a CD47 decoy receptor, designed to block the “don’t eat me” signal on tumor cells, facilitating macrophage-mediated phagocytosis and immune clearance. Azacitidine is a hypomethylating antineoplastic agent that inhibits DNA methyltransferase resulting in DNA hypomethylation and cytotoxicity to abnormal hematopoietic cells. Venetoclax is a selective, orally bioavailable small molecule inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL-2), restoring apoptotic processes in malignant cells. The combination is under early-phase investigation for newly diagnosed or relapsed/refractory AML, particularly in elderly or unfit patients, and exhibits synergistic anti-tumor activity in preclinical models.